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Abstract
Background: Important advances in the development and production of quality-certified pediatric antiretroviral
(ARV) formulations have recently been made despite significant market disincentives for manufacturers. This
progress resulted from lobbying and innovative interventions from HIV/AIDS activists, civil society organizations,
and international organizations. Research on uptake and dispersion of these improved products across countries
and international organizations has not been conducted but is needed to inform next steps towards improving
child health.
Methods: We used information from the World Health Organization Prequalification Programme and the United
States Food and Drug Administration to describe trends in quality-certification of pediatric formulations and used
7,989 donor-funded, pediatric ARV purchase transactions from 2002-2009 to measure uptake and dispersion of new
pediatric ARV formulations across countries and programs. Prices for new pediatric ARV formulations were
compared to alternative dosage forms.
Results: Fewer ARV options exist for HIV/AIDS treatment in children than adults. Before 2005, most pediatric ARVs
were produced by innovator companies in single-component solid and liquid forms. Five 2-in1 and four 3-in-1
generic pediatric fixed-dose combinations (FDCs) in solid and dispersible forms have been quality-certified since
2005. Most (67%) of these were produced by one quality-certified manufacturer. Uptake of new pediatric FDCs
outside of UNITAID is low. UNITAID accounted for 97-100% of 2008-2009 market volume. In total, 33 and 34
countries reported solid or dispersible FDC purchases in 2008 and 2009, respectively, but most purchases were
made through UNITAID. Only three Global Fund country recipients reported purchase of these FDCs in 2008. Prices
for pediatric FDCs were considerably lower than liquids but typically higher than half of an adult FDC.
Conclusion: Pediatric ARV markets are more fragile than adult markets. Ensuring a long-term supply of quality,
well-adapted ARVs for children requires ongoing monitoring and improved understanding of global pediatric
markets, including country-based research to explain and address low uptake of new, improved formulations.
Continued innovation in pediatric ARV development may be threatened by outdated procurement practices failing
to connect clinicians making prescribing decisions, supply chain staff dealing with logistics, donors, international
organizations, and pharmaceutical manufacturers. Perceptions of global demand must be better informed by
accurate estimates of actual country-level demand.
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Background
Accessing quality treatment and care remains an uphill
battle for families of children living with HIV/AIDS in
resource-poor settings. For many years, the lack of easy-to-
use pediatric formulations for some antiretroviral (ARV)
medicines and the high costs of others hindered efforts to
deliver medical care to this vulnerable population [1].
From an industry perspective, the disincentives to
develop and produce pediatric ARVs are numerous and
powerful. Pediatric ARV markets are always smaller and
less attractive than adult markets. In the United States
and Europe, HIV infections in infants and young children
have been nearly eliminated [2], leaving little demand for
pediatric ARV formulations in these markets.
In order to develop new pediatric dosage forms for
use in developing countries with larger pediatric ARV
demand, additional research must first be conducted in
children, including costly clinical trials, bioequivalence,
bioavailability, dose-ranging, and pharmacokinetic stu-
dies [3,4]. The implementation of comprehensive ser-
vices to prevent mother-to-child transmission (PMTCT)
of HIV remains low in many countries [5]; however, if
recent initiatives to reduce vertical HIV transmission are
successful [6], pediatric antiretroviral demand will
further diminish, reducing any returns on investment
for developing pediatric ARVs. After development, the
per-unit production costs of pediatric ARVs are likely
high because small quantities impede the realization of
economies of scale in production and distribution [3].
Further compounding these disincentives are the
innate complexities of pediatric formulation markets.
Numerous products are needed in varying strengths to
accommodate changing doses as children grow, which
fragments the pediatric market for a given ARV into
even smaller niches. Moreover, as children move
through infancy, toddler, and childhood stages, the opti-
mal dosage form changes as well. Liquids (syrups, sus-
pensions, and solutions) are needed to treat infants but
pose logistical challenges: many need refrigeration and,
because of large bottle sizes and heavy weight, are diffi-
cult for families to carry home. In low resource settings,
measuring and delivering the correct liquid doses can
also be challenging. Powders and dispersible tablets that
can be mixed with water are an option, but they require
access to clean water and often have unpleasant tastes
that are unacceptable to infants. As children get older
and the necessary volumes of liquid ARVs become too
large, they require other products, such as chewable
tablets and sprinkles, until they reach an age when they
can swallow solid tablets [7].
Despite these market disincentives for pharmaceutical
manufacturers, fortunately, important advances have
recently been made in the development and production
of pediatric ARV formulations quality-certified by the
World Health Organization (WHO) Prequalification
Progamme [8], the United States (US) Food and Drug
Administration (FDA) [9,10], or other stringent regula-
tory authorities. This progress can be credited to persis-
tent lobbying and innovative interventions from HIV/
AIDS activists, civil society organizations, and interna-
tional organizations.
Médecins Sans Frontières, for example, has consis-
tently drawn attention to the particularly glaring neglect
of children in HIV/AIDS treatment programs and sug-
gested that the lack of child-friendly versions of ARVs
contributes to high rates of HIV/AIDS deaths in chil-
dren under two years of age [11,12]. In November 2004,
the United Nations Children’s Fund (UNICEF) and
WHO held a technical consultation on improving access
to appropriate pediatric ARV formulations during which
experts identified missing pediatric formulations consid-
ered to be high priority and discussed ways to galvanize
pharmaceutical companies to produce them [7]. Shortly
thereafter, two global initiatives were launched. Unite for
Children, Unite Against AIDS, was begun by UNAIDS,
UNICEF, and others in 2005 as a platform for all part-
ners engaged in pediatric HIV/AIDS programs [13]. The
first WHO Model List of Essential Medicines for Chil-
dren was released in 2007 [14] and Make medicines
child size, led by WHO, was launched in late 2007 to
raise awareness and improve access to medicines that
are safe for children under age 12 [15].
On the implementation side, both the United States’
President’s Emergency Plan for AIDS Relief (PEPFAR)
[16] and UNITAID [17] made commitments to priori-
tize the needs of children. The Clinton Health Access
Initiative (CHAI) [18] and the Supply Chain Manage-
ment System (SCMS) [19] conduct large-scale purchas-
ing on behalf of UNITAID and PEPFAR, respectively.
Given the substantial overlap of funding in some coun-
tries by UNITAID, the Global Fund to Fight AIDS,
Tuberculosis, and Malaria (GFATM) [20], and PEPFAR,
agreements were made with countries and major donors
that UNITAID would initially be the primary source of
funding for pediatric ARVs (D Jamieson, SCMS, perso-
nal communication) in those countries. Such coordina-
tion allows for optimization of resources and avoidance
of service duplication. In countries where UNITAID and
PEPFAR are not active, GFATM-supported HIV/AIDS
programs procure their ARVs independently.
The will of these international organizations to invest
in pediatric antiretroviral therapy (ART) created incen-
tives for producers to enter the market, as manufac-
turers could be relatively certain of a minimum volume
of purchases from reliable clients [21,22]. The ensuing
scale-up of ARV delivery to children in developing
countries then progressed dramatically. Whereas only
10% of children in need were being treated in 2005, 38%
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were receiving ART by the end of 2008 [5]. However,
despite these advances in product development and
treatment coverage, the literature suggests that retaining
children in HIV/AIDS programs remains problematic
[23,24]. In 2009 the Clinton Foundation reported infant
losses to follow-up of 32% (in Cameroon) and 53% (in
an eight-country meta-analysis) [25].
Clearly, critical challenges remain. Three out of five
children needing ART are not receiving it [5]. A preli-
minary examination of ARV purchase data suggests that
many countries are not yet using new, improved pediatric
formulations [26,27]. Finally, there are a number of ARVs
for which appropriate pediatric formulations are still not
available. According to Médecins Sans Frontières, appro-
priate pediatric formulations are still lacking for a range
of important ARVs, including efavirenz, darunavir and
other ritonavir-boosted protease inhibitors (in addition
to lopinavir/ritonavir) [28].
Most pediatric fixed-dose combinations (FDCs) devel-
oped to date have included stavudine and zidovudine.
Aside from low demand, few barriers existed for the
development of these products. A substantial amount of
research had already been conducted on these ARVs in
children, patents were generally absent or unenforced
[29], and manufacturers had lots of experience produ-
cing adult versions. In contrast, for newer ARVs, little
research has been conducted in children, patent barriers
are more widespread, and manufacturers have less
experience producing adult FDCs containing these
ARVs. To ensure that companies develop pediatric ver-
sions of these medicines, a better understanding is
needed of both the supply and the demand side of the
pediatric ARV market. However, to date, no research
has been published on the characteristics or the evolu-
tion of this market.
In order to fill this knowledge gap, this paper exam-
ines trends in the availability of WHO-recommended
ARVs in quality-certified pediatric formulations, and
describes the rate and extent of product uptake across
developing countries and among international donors to
guide next steps towards improving child health.
Methods
We utilized an ARV market intelligence database com-
prised of data from multiple sources, including product
approvals by the US FDA [9,10] and certifications by
the WHO Prequalification Progamme [8]. This database
is described in more detail elsewhere [30-32]. Into it we
merged 2009 transactional data of donor-funded ARV
purchases provided directly to researchers by the Clin-
ton Health Access Initiative (CHAI) [18] on behalf of
UNITAID [17] and the Supply Chain Management Sys-
tem (SCMS) [19] on behalf of PEPFAR [16] as well as
publicly posted transactions in the WHO Global Price
Reporting Mechanism [27] and the GFATM Price Qual-
ity Report [26] from 2002-2009. Information and algo-
rithms in the market intelligence database were used to
clean and validate ARV transactional data, which was
then limited to purchases made for ARV formulations
predominantly used in children (Figure 1).
We examined trends in quality-certification of pedia-
tric ARVs by WHO [8] and the FDA [9,10] in relation
to treatment regimens recommended by WHO for
infants and children [33,34]. We also described purchase
trends for pediatric ARV formulations (liquid, solid, dis-
persible), including numbers of purchasing countries,
from 2004 to 2009. A solid product is defined as a med-
icine intended to be swallowed, while a dispersible ARV
tablet dissolves when placed in a small amount of water.
Liquids are syrups, solutions, and suspensions. We dif-
ferentiate single-component ARVs from FDC dosage
forms with the labels “single” and “FDC”. We describe
FDC products using a “/” between ARVs included in a
given FDC and use the terms brand and innovator inter-
changeably to denote the initial developer of a medicine.
We calculated trends in purchaser (GFATM, SCMS,
UNITAID) market share by value for brand and generic
pediatric dosage forms from 2002 to 2009. For FDC ver-
sions of pediatric ARVs, we provided percent purchaser
market share by volume for 2008 and 2009.
Price comparisons of ARV dosage forms (pediatric
FDC, liquid, and adult FDC) were calculated using
prices paid by CHAI/UNITAID based upon WHO-
recommended doses [33,34] and presented as price per
person per year in United States dollars (USD). All
ARV prices provided by GFATM, WHO, CHAI, and
SCMS in USD were adjusted to the January-December
2009 time period using the annual US Consumer Price
Index [35].
Results
Priority pediatric ARVs: WHO recommendations,
production and purchase trends
In 2007, the WHO Paediatric Antiretroviral Working
Group identified a total of 40 priority pediatric ARV
products (19 urgent, 10 high, and 11 important) for
pediatric HIV/AIDS treatment (Table 1) [33]. Only 17
of the 40 pediatric ARV products were categorized by
WHO as “ideal” dosage forms. Sixteen of the 40 recom-
mended ARV products were actually produced and pur-
chased by countries for pediatric HIV/AIDS treatment.
Some new pediatric products originally produced and
purchased are no longer in demand because subsequent
changes in dosing guidelines meant the new formula-
tions no longer matched the revised dosing recommen-
dations. In 2009, the WHO Expert Committee on the
Selection and Use of Essential Medicines revised the list
of priority pediatric ARVs to include 17 of the 18 ARVs
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originally categorized as ideal in 2007 (Table 1) plus one
new formulation (ABC60/NVP50/ZDV60) and one new
ARV (atazanavir) [36].
Overview of FDA-approved and WHO-prequalified
pediatric ARVs
Prior to 2002, 23 of 24 (96%) FDA-approved pediatric
formulations were produced by innovator companies
(Figure 2), reflecting demand from patent-protected mar-
kets in the US and Europe. The establishment of the
GFATM in 2002 created instantaneous demand for
affordable ARVs in developing countries, many of which
overcame intellectual property barriers to purchase low-
cost generic medicines [29]. Eighteen pediatric ARVs (14
innovator and four generic) were certified by WHO in
2002, the first year of the program, but only three formu-
lations were pre-qualified in the following three years.
Over the entire time period a total of 113 ARV formu-
lations produced by eight innovator and eight generic
manufacturers were certified. Most innovator ARVs were
approved before 2005 and most generic ARVs were
approved in 2005 or later. Examination of all certifica-
tions by dosage form reveals 44 liquid, 55 solid, seven
chewable, and seven dispersible products. All dispersible
products were generic and certified in 2007 or later.
For the majority of pediatric FDCs, only one manufac-
turer is quality-certified by either the WHO or the FDA.
Six of nine (67%) solid and dispersible FDCs are produced
by only one quality-certified manufacturer (Figure 3).
Similar patterns exist for other pediatric ARV dosage
forms with six solid single-component ARVs and eight
liquid ARVs supplied by only one quality-certified
producer.
Among pediatric ARVs purchased and reported (both
quality-certified and non-quality certified), eight solid
and dispersible FDCs were supplied by only one manu-
facturer (Figure 3). Many single component solid ARVs
and liquid ARVs, however, were supplied by two or
more manufacturers.
The 2002 WHO first-line treatment guidelines for
infants and children included five ARVs and three regi-
mens [37] (Table 2). In 2006, the WHO revised their
guidelines to include six ARVs and six preferred first-line
regimens [34]. Approximately 68% of all WHO and FDA
product certifications were for ARVs recommended by
WHO in first-line regimens. Four and six preferred sec-
ond-line regimens, all of which contain didanosine and a
protease inhibitor, were listed on WHO 2002 and 2006
guidelines, respectively. A 2008 guidance by WHO listed
three first-line regimens as well as three regimens for
infants exposed to certain ARVs
Because limited research has been conducted in chil-
dren with HIV/AIDS, fewer ARV treatment options
exist for infant and children as compared to adults. This
lack of pediatric research is particularly relevant for
newer ARVs. Whereas tenofovir is now recommended
by the WHO for first-line treatment of adolescents and
adults [38,39] and is being widely adopted by countries,
Figure 1 Data overview.
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Table 1 Priority pediatric ARV formulations
Pediatric ARV
Dosage Form
2007 WHO
Recommendation
Ideal Dosage
Form
Produced and
purchased
2009 WHO
Recommendation
3TC30/NVP50/ZDV60 Urgent yes yes yes
3TC30/NVP60/ZDV60 Urgent
3TC75/NVP100/ZDV150 Urgent
3TC30/ZDV60 Urgent yes yes yes
3TC75/ZDV150 Urgent
3TC30/d4T6 Urgent yes yes yes
3TC75/d4T15 Urgent
3TC30/NVP50/d4T6 Urgent yes yes yes
3TC20/NVP35/d4T5 Urgent yes
3TC30/NVP50/d4T7 Urgent
3TC60/NVP100/d4T12 Urgent yes
3TC40/NVP70/d4T10 Urgent yes
NVP 50 Urgent yes yes
NVP 100 Urgent
LPV100/r25 Urgent yes yes yes
LPV90/r22.5 Urgent
ABC 60 Urgent yes yes yes
ABC 120 Urgent
ABC 150 Urgent
EFV 100 High yes yes yes
EFV 600 High yes
ABC60/3TC30 High yes yes yes
ABC150/3TC75 High
ZDV 60 High yes yes
ZDV 100 High yes
ABC60/3TC30/ZDV60 High yes yes
ABC150/3TC75/ZDV150 High
d4T 6 High yes yes
d4T 15 High
ddI 125 Important yes
ddI 200 Important yes
3TC 30 Important yes yes
3TC 75 Important
3TC 150 Important yes
EFV100/FTC35 Important yes yes
FTC 35 Important yes yes
RTV 25 Important yes yes
RTV 100 Important
FPV* Important yes yes
DRV* Important
ABC60/NVP50/ZDV60 yes
ATV* yes
*dose to be determined.
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tenofovir is not recommended for use in infants and
children due to insufficient research on safety and toxi-
city [34].
Because of interactions between nevirapine and rifam-
picin (anti-tuberculosis medicine), the WHO recom-
mends use of efavirenz in place of nevirapine for HIV/
AIDS in adults with tuberculosis co-infection [38]; how-
ever no data is available on safety and efficacy of efavir-
enz in children under three years of age [34].
Pediatric HIV/AIDS treatment options are further
reduced if newborns were exposed to single dose nevira-
pine for PMTCT or maternal non-nucleoside reverse
transcriptase inhibitor (NNRTI) therapy. When pro-
tease-inhibitors are used for first-line treatment in
infants with NVP and/or NNRTI maternal exposure,
infants and children are left with few ARV options for
second-line treatment [40]. Whereas boosted darunavir,
etravirine, and raltegravir are potential options in adults
who fail protease inhibitor regimens [39], none of these
options are available in pediatric formulations and little
research on use of these ARVs in children has been
conducted.
Only one pediatric ARV FDC (LPV/r) existed before the
establishment of the GFATM and it was only available in
a liquid form requiring refrigeration. The first pediatric
3-in-1 FDC to accommodate WHO-recommended first
line regimens was quality-certified in 2007 (Table 3), lag-
ging four years behind the first adult version.
Since 2005, a total of five 2-in-1 pediatric FDCs and
four 3-in-1 pediatric FDCs had been FDA-approved
and/or WHO-prequalified. Eight of these nine (89%)
FDCs support first-line regimens. The first pediatric
heat-stable, ritonavir-boosted protease inhibitor (LPV/r)
was certified in 2005 and remains the only FDC avail-
able to support second-line treatment in children. The
first dispersible tablets were approved in 2005 with five
FDCs available by the end of 2009.
Purchase trends and market share for pediatric ARVs
Few countries purchased pediatric ARVs before 2004.
The number of countries purchasing liquid and solid
single-component pediatric ARVs increased steadily
from 43 and 26, respectively in 2004 to 85 and 64,
respectively in 2008 (Figure 4). These liquid and solid
single-component products were reported by large num-
bers of countries across GFATM, UNITAID, and Mis-
cellaneous categories.
A total of 33 and 34 countries reported either solid or
dispersible pediatric FDC purchases in 2008 and 2009,
respectively. Pediatric FDC purchases, however, have
been largely limited to countries supported by UNITAID,
with 29 and 31 countries reporting FDC purchases (solid
Figure 2 Trends in innovator and generic pediatric ARV formulations certified by WHO and FDA*. *Includes all pediatric ARV approvals
for all manufacturers; overlap between FDA approval and WHO prequalification exists as some products are certified by both organizations.
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and dispersible) in 2008 and 2009, respectively. Only
three GFATM countries reported pediatric FDC ARV
purchases in 2008, while SCMS reported pediatric FDC
purchases for only two countries in 2008 and 2009.
Looking more closely at purchase trends for different
FDC dosage forms, purchases for dispersible FDCs were
first reported in 2005 but increased sharply in 2007 with
28 countries reporting purchase transactions. UNITAID
accounted for 26 of the 28 (93%) countries reporting
dispersible FDC purchases. This trend continues
through 2009 when UNITAD reported dispersible FDC
purchases in 26 countries and no other purchases were
reported outside of UNITAID.
Similar purchase trends are noted for solid pediatric
FDCs whereby UNITAID reported purchase transac-
tions for 16 and 28 countries in 2008 and 2009, respec-
tively, while very few countries outside of UNITAID
reported solid FDC transactions.
The total donor-funded pediatric ARV market
increased from approximately US $5 million in 2004 to
$34 million in 2008, with total 2009 purchases likely to
be more than $40 million once reporting is complete
Figure 3 Number of manufacturers certified and reported to supply each pediatric ARV.
Table 2 WHO-recommended regimens for infants and children
Year of WHO Guideline First-Line Regimen Second-Line Regimen
2002 ZDV + 3TC + ABC d4T + ddI + PI* or d4T + ddI + (EFV or NVP)
ZDV + 3TC + (NVP or EFV) d4T + ddI + PI*
2006 Preferred (ZDV or d4T) + 3TC + (NVP or EFV) ddI + ABC + PI**
ABC + 3TC + (NVP or EFV) ddI + ZDV + PI**
2006 Alternative (ZDV or d4T) + 3TC + ABC ddI + (EFV or NVP) +PI**
2008*** (ZDV or d4T or ABC) + 3TC + NVP
(ZDV or d4T or ABC) + 3TC + LPV/r
*PI options include LPV/r and NFV.
**PI options include LPV/r, SQV/r, and NFV.
***Infants <12 months of age.
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(Figure 5). While the pediatric ARV market has grown
rapidly, its current size is a small fraction of the US
$500 million reported thus far in 2009 for adult ARV
solid dosage forms.
From 2007 to 2009 UNITAID accounted for 62-93%
of generic purchases, while the GFATM accounted for
62-74% of all innovator purchases. Careful examination
of 2009 GFATM brand purchases reveals that the Rus-
sian Federation and South Africa account for 80% and
14% of all GFATM branded spending, respectively, and
59% and 10% of branded spending, respectively, of all
donor purchases. The Russian Federation purchased five
branded liquids (ZDV, NVP, 3TC, ddI, ABC) and South
Africa purchased one branded liquid (LPV/r). The
remaining GFATM countries account for only 6% of
2009 GFATM branded ARV purchases.
Further examination quantifies the low uptake of disper-
sible and solid pediatric FDCs outside of UNITAID. In
2008, UNITAID accounted for 100% of market volume for
five of eight FDCs and 97-99% of market volume for the
remaining three FDCs (Figure 6a). UNITAID held similar
pediatric FDC market dominance in 2009 (Figure 6b).
Price comparisons of pediatric ARV formulations
Prices for all pediatric ARV formulations continue to
drop, with FDCs remaining consistently less expensive
than liquid formulations (Table 4). Liquid alternatives
Table 3 Initial quality certification of FDC pediatric ARVs*
2000 2005 2007 2008 2009
2-in-1 FDCs
ABC60/3TC30 solid
3TC30/d4T6 dispersible
3TC60/D4T12 dispersible
3TC30/ZDV60 solid
LPV100/RTV25 solid
LPV80/RTV20 per ml liquid
3-in-1 FDCs
ABC60/3TC30/ZDV60 solid
3TC30/NVP50/d4T6 dispersible
3TC60/NVP100/
d4T12
dispersible
3TC30/NVP50/ZDV60 dispersible
*recommended on 2006 WHO pediatric HIV/AIDS treatment guidelines.
Figure 4 Country pediatric ARV purchase trends, by purchaser, 2004-2009*. *total number of unique countries purchasing ARV dosage
form is indicated in text boxes (some overlap of countries across some donor programs).
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were 2.3-3.2 times more expensive than dispersible pro-
ducts for stavudine-based FDCs in 2009 and ranged
from 1.4-1.6 times more expensive than solid versions
of zidovudine- and abacavir-based FDCs.
Some treatment programs treat children with half of
an adult FDC once they reach weights of at least 10 kg.
Prices for half of a stavudine-based adult FDC are 29-
42% less expensive than the two stavudine-based pedia-
tric FDCs.
Discussion
In past years, great strides have been made in bringing
to market quality-certified, pediatric ARV FDCs in
dosage forms appropriate for use in low resource set-
tings. Activists, international organizations and national
governments have successfully lobbied for the develop-
ment and production of pediatric ARV products. Five
new 2-in-1 and four new 3-in-1 pediatric FDCs have
been quality-certified by the WHO or FDA since 2005
in dosage forms appropriate for use in low resource set-
tings. These new products include the first heat-stable,
ritonavir-boosted protease inhibitor and five ARVs avail-
able as dispersible tablets, a formulation typically more
acceptable to children than liquids and substantially less
expensive, easier to store, less costly to distribute to
health care facilities, and easier for care takers to carry
home than liquid alternatives. The new solid and disper-
sible pediatric FDCs offer ease of administration and
more reliable dosing than crushing or multiple-splitting
of adult FDCs.
Despite these advantages, however, country purchases
for ARVs in less desirable dosage formulations (liquid
and solid, single-component ARVs) continue to show
annual increases while uptake of the new solid and
dispersible FDCs has been remarkably low outside of
UNITAID-funded programs. UNITAID accounted for
97-100% of total market volume for all solid and disper-
sible pediatric FDCs purchased with donor-funds in
both 2008 and 2009.
The GFATM provided funds to 116 countries for
HIV/AIDS in 2008 [41] while UNITAID reported finan-
cing pediatric HIV/AIDS treatment in 44 countries by
Figure 5 Pediatric ARV market trends (value), 2003-2009.
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the end of 2009 [42]. The GFATM, SCMS, and UNI-
TAID agreed that UNITAID would lead pediatric ARV
procurement in countries they support, with UNITAID
reporting pediatric ARV FDC purchases for 29 and 31
countries in 2008 and 2009, respectively. Only three and
two countries from GFATM and SCMS, respectively,
reported pediatric FDC ARV purchases in 2008. While
donor coordination explains lack of FDC purchases in
GFATM countries also receiving UNITAID funds,
uptake of new pediatric FDCs in GFATM countries
without UNITAID funding is remarkably low.
This study cannot explain the reasons for low uptake of
improved pediatric formulations outside of UNITAID.
Our results reveal the importance of additional operational
Figure 6 Purchaser market share (volume) for solid & dispersible pediatric FDCs, 2008 and 2009. a. Pediatric FDC ARV Market Share
(volume) by purchaser, 2008. b. Pediatric FDC ARV Market Share (volume) by purchaser, 2009.
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research to identify barriers to product use. Still, we pre-
sent some potential challenges at country level that may
prevent or delay adoption of new products. To start, coun-
try-based staff may be unaware of recent developments
and availability of new pediatric formulations. There may
be reluctance to use new formulations, such as dispersible
tablets, in regions where these types of medicines are not
historically or currently used. Regulatory barriers, registra-
tion costs and difficulties, the need to revise treatment
guidelines and the need to retrain all prescribers and care-
givers may also contribute to under-utilization. Countries
may be locked into long-term contracts that preclude
them from switching to improved products or their
demand may be too low to meet some suppliers’ mini-
mum purchase requirements.
To change from currently used ARVs to the new
pediatric formulations may also produce challenges in
supply chain management. Demand forecasting (i.e.
determining the amount of medicine needed for country
programs) is a challenging and complicated task [43]
and insufficient focus has been placed on improving
outdated procurement practices. It is possible that in
the transition phase from one set of ARVs to another,
the number of pediatric products in warehouses and on
facility shelves increases substantially, making demand
forecasting more complicated for some period of time.
Thus, such transitions need to be carefully planned and
monitored in order to avoid wastage and stock
shortages.
It is also possible that the types of pediatric products
created to date are not the products most desired at
country level, or that practitioners and caregivers prefer
to use half of an adult FDC instead of pediatric FDCs,
when possible. Using adult FDCs for children in lieu of
pediatric FDCs may simplify supply chain management
of ARVs (procurement, storage, distribution, inventory
management) as well as prescribing, dispensing, and
administration by the caregiver. Lastly, countries may
currently be in the process of transition and we are now
observing a time lag between decisions to switch to
newer products and actual implementation of those
decisions.
While it is thus understandable for a number of rea-
sons that the adoption of new, improved pediatric ARVs
is a time-consuming process, such inertia may have
undesirable side effects. For instance, it may falsely sig-
nal to pharmaceutical companies that the markets for
improved pediatric ARVs are smaller than anticipated
because of logistical and acceptability problems, deter-
ring entry of new manufacturers and scale-up of pro-
duction among existing ones [28].
International organizations and countries already face
challenges obtaining existing pediatric ARV medicines.
Reports that Bristol-Myers Squibb will encounter inter-
ruptions in the production of pediatric didanosine have
created great concern for upwards of 7,000 children
treated with this medicine [44,45]. Bristol-Myers Squibb
is currently the only quality-certified producer of pedia-
tric didanosine tablets and the amount of didanosine
currently available may be insufficient to meet the needs
of children on treatment during the period of supply
interruption. Médecins Sans Frontières reports difficulty
purchasing the quality-certified pediatric 3TC/ZDV due
to low-volume purchase requests (G Arreghini, Méde-
cins Sans Frontières, personal communication). Méde-
cins Sans Frontières also notes difficulty obtaining the
Table 4 Price comparison of ARV dosage forms, 2008-2009*
Pediatric
Defined Daily Dose
2008
Price/Person/Year (USD)
2009
Price/Person/Year (USD)
Weight
(kg)
Liquid
(ml)
Pedi
FDC
(tab)
Adult
FDC
(tab) Liquid
Pedi
FDC
Adult
FDC Liquid
Pedi
FDC
Adult
FDC
2-in-1 FDCs
ABC60/3TC30 5 6/6 2 175 - 142 89
3TC30/d4T6** 5 6/12 2 69 27 52 23
3TC60/D4T12** 10 12/24 2 1 139 50 29 105 40 24
3TC30/ZDV60 5 6/12 2 71 44 56 40
LPV100/RTV25 15 5 4 2 323 306 287 286 268 228
3-in-1 FDCs
ABC60/3TC30/ZDV60 5 6/6/12 2 181 - 194 -
3TC30/NVP50/d4T6** 5 6/10/12 2 122 33 83 29
3TC60/NVP100/d4T12** 10 12/20/24 2 1 244 54 40 166 52 37
3TC30/NVP50/ZDV60** 5 6/10/12 2 123 56 86 53
*based upon UNITAID prices reported by Clinton HIV/AIDS Initiative.
**dispersible FDC.
Waning et al. BMC Pediatrics 2010, 10:74
http://www.biomedcentral.com/1471-2431/10/74
Page 11 of 14
quality-certified pediatric ABC/3TC/ZDV, a new FDC
not purchased by CHAI/UNITAID and therefore in low
demand.
Even when pediatric ARVs are procured by large-scale
purchasers like UNITAID, an unfortunate paradox
comes into play in pediatric HIV/AIDS treatment: the
more that pediatric ARV formulations are tailored to
the needs of specific sub-groups, the less demand
there is for a given product. This becomes particularly
problematic in convincing companies to produce age-
appropriate strengths of fixed-dose combination ARVs
in multiple formulations. The WHO list of priority
ARVs needs to be complete but also succinct, to aggre-
gate demand around the most important products and
avoid the development and production of ARVs that go
unused by countries.
Because of the inherent disincentives for manufac-
turers in the pediatric ARV market, extreme care must
be taken to ensure that price negotiations between pro-
ducers and large-scale purchasers are conducted in a
manner that ensures sufficient profit to sustain prices
and stabilize the market over the long term. Activists,
civil society organizations, researchers, international
organizations and others must not only lobby for pedia-
tric investments, but also monitor the movement of
manufacturers in and out of the pediatric market, the
extent and rate of new product uptake and their impact
on child health. If countries are in a transition to new
products, it is important for donors and suppliers to
know and predict the amount of time needed for such
transitions.
Operational research to identify and address reasons
for low product utilization is a critical next step towards
meeting two major global targets for 2015: Millennium
Development Goal (MDG)-4, calling for a two-thirds
reduction in mortality rates for children under five, and
MDG-6, which aims to halt and begin to reverse the
spread of HIV [46].
Success in the case of pediatric HIV/AIDS treatment
cannot be determined only by market availability of new
and improved ARV products. Until the barriers to
uptake can be identified and addressed, and country
demand stabilizes, organizations like UNITAID which
offer the equivalent of advance market commitments
will be needed to encourage the entry of new manufac-
turers and “hold the market” until countries can adopt
the newer formulations.
Limitations
While we systematically cleaned and validated purchases
[30-32], it is possible that misreported purchases are
still present in our analytic data set. The historical
GFATM ARV transactional data posted in WHO
GPRM, in particular, required considerable cleaning. We
note a substantial number of ARV transactions in the
“miscellaneous” category. Most of these miscellaneous
transactions were reported by procurement agencies and
we suspect many of these miscellaneous reports are
actually purchases made by GFATM recipients. ARV
transactions for GFATM recipients have been inconsis-
tent in both the older GFATM Purchase Price Report
and the WHO GPRM. We observed many instances
over the past few years when transactions appeared and
disappeared from both of these databases.
For this paper, we used 2002-2009 purchases down-
loaded from the WHO and GFATM on 1 May, 2010. We
noted the absence of SCMS, UNITAID, and GFATM
purchases in the WHO GPRM after April 2009 and
therefore obtained this information directly from those
organizations. The GFATM data was publicly available
on its website. CHAI provided ARV purchase data to
researchers on behalf of UNITAID without restrictions
and SCMS staff provided transactional data to research-
ers under conditions that they review and comment on
manuscripts utilizing their data prior to submission.
Recent interventions to improve the quality of transac-
tions in the GFATM PQR have resulted in longer delays
from the time countries report purchases to public post-
ing. Our data therefore underestimate 2009 GFATM
purchases. It is possible that GFATM-supported coun-
tries purchased new pediatric formulations in 2009 that
do not yet appear in publicly posted data. In addition,
some organizations (i.e., World Bank, PEPFAR pur-
chases outside of SCMS, Médecins Sans Frontières) do
not report ARV purchases to the WHO GPRM. Simi-
larly, governments that purchase ARVs with their own
funds do not report transactions to WHO. Delays in
reporting, data restrictions imposed by some donors,
and unwillingness to report ARV purchases will limit
the ability to monitor and evaluate global ARV markets
in a timely and unbiased manner.
We limited our analytic data set to ARV formulations
used predominantly in children and infants. Our ana-
lyses did not include three ARVs (3TC150, EFV 600,
and DRV) listed as pediatric ARVs by WHO (Table 1)
as these are more commonly used for adults.
We calculated ARV regimen prices for new and liquid
formulations using UNITAID/CHAI-reported prices
because UNITAID was the only consistent purchaser of
FDCs. These prices may not accurately reflect prices paid
by countries outside of UNITAID programs. We acknowl-
edge that some programs may still be splitting adult FDCs
into quarters or crushing adult FDCs for use in children.
We did not compare pediatric FDC prices to quarters of
adult FDCs because WHO recommends against splitting
adult tablets more than one time [33].
Liquid ARV prices are the most difficult to clean and
validate given the multitude of different ways countries
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have misreported purchases. The Russian Federation
accounted for more than 80% of GFATM brand pur-
chases in 2008. It is possible that the Russian purchases
were reported in error, but prior benchmarking price
analysis of ARV purchases in the Former Soviet Union
revealed that Russian prices (confirmed with procure-
ment staff) were consistently and remarkably higher
than other countries [47].
In addition, these Russian purchases passed through
new quality improvement processes implemented when
the new PQR system at the GFATM was recently
established.
Conclusion
Treatment of children with HIV/AIDS is a high priority
for the international community. However, ensuring
that needed pediatric medicines are developed and deliv-
ered to those who need them remains a complex, chal-
lenging task. In order to improve performance in this
area, a better understanding of the pediatric ARV mar-
ket is needed - where it is performing well, and where
substantial market failures persist.
This study has demonstrated that the pediatric ARV
market is not simply a smaller version of the adult mar-
ket (described elsewhere [30-32]). Compared to HIV/
AIDS treatment options for adults, far fewer ARVs have
been proven safe and effective in children. Whereas mul-
tiple donors and countries buy substantial quantities of
adult first-line ARVs, one international institution, UNI-
TAID, plays a dominant role in the pediatric market,
buying an overwhelming proportion of some pediatric
ARVs. Pediatric markets become fragmented into niches
with little demand as manufacturers develop more accep-
table, age-appropriate pediatric products, and adopting
improved formulations may present logistical challenges
in some countries. While most adult FDCs are produced
by several quality-certified manufacturers, many pediatric
FDCs have only one quality-certified manufacturer, leav-
ing HIV/AIDS treatment programs highly dependent on
a single supplier to meet global demand.
Ensuring a long-term supply of high-quality, effective,
affordable and well-adapted ARVs for children in differ-
ent age groups will require ongoing monitoring and
improved understanding of the global pediatric ARV
market. Furthermore, much research is required at
country level to understand better why uptake of new,
improved formulations has been so slow, and what can
be done to accelerate children’s access to quality AIDS
care in resource-poor settings. Continued innovation in
pediatric ARV development may be threatened by out-
dated procurement practices failing to connect clinicians
making prescribing decisions, supply chain staff dealing
with logistics, donors, international organizations, and
pharmaceutical manufacturers. Perceptions of global
demand must be better informed by accurate estimates
of actual country-level demand.
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